Experimental drug aims to stop leukemia relapse after transplant

NCT ID NCT04623216

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called sabatolimab, alone or with another drug, in 24 adults and teens with acute myeloid leukemia (AML) who had signs of leftover cancer after a stem cell transplant. The goal was to see if it could prevent the cancer from coming back without causing severe side effects like graft-versus-host disease. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Freiburg im Breisgau, 79106, Germany
Novartis Investigative Site

Hamburg, 20246, Germany
Novartis Investigative Site

Münster, 48149, Germany
Novartis Investigative Site

Bergamo, BG, 24127, Italy
Novartis Investigative Site

Bologna, BO, 40138, Italy
Novartis Investigative Site

Brescia, BS, 25123, Italy
Novartis Investigative Site

Roma, RM, 00165, Italy
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.